A recent study reveals that individuals who stop using popular slimming jabs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who stop conventional diet and exercise programs.
Findings released in a prominent medical journal demonstrates that while overweight people frequently drop substantial amounts of their body weight while on the medication, the weight returns at an estimated rate of nearly a kilo each month after stopping.
"People using these medications should be informed of the potential of rapid rebound weight gain when the medication is stopped," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery implies a return to original mass in about one and a half years.
Weighing Approaches
The analysis, which reviewed 37 of studies involving over 9,000 of patients, compared the results of these new drugs with other pills.
Researchers note that people who lose weight through dieting usually experience a less rapid creep back—approximately 0.1 kg a month—once they finish.
Explaining the Quick Rebound
Experts propose the mechanism of the jabs accounts for the amplified weight return.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 levels several times higher than normal could lead to the system to produce less of its own natural hormone, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a dietetics expert.
"Discontinuation of this hormone supplement results in hunger is unsuppressed, making overeating a significant risk."
A Lifelong Issue?
Medical guidelines advise the jabs for individuals with weight-linked health risks, alongside prescribed diet and exercise modifications.
Professionals argue that, given the significant potential of relapse, the therapy is often life-long.
This opinion is reinforced by drug manufacturers, who note that the results "underscore the persistent nature of obesity," akin to managing conditions like diabetes.
Patient Testimonies
Users who have stopped the medication explain a sudden return of appetite.
"It felt as if something activating and you become extremely hungry," said an individual.
This difficulty is exacerbated if patients have not adopted sustainable dietary or behavioural changes during therapy.
Significant Use
Survey data suggest that millions of adults in the UK have used these injections in the last 12 months, with desire being substantial.
- Adoption is greater among females compared to men.
- The 40s and 50s age group shows the highest usage rates.
- Many access the drugs through private healthcare rather than the NHS.
Finally, clinicians stress that while these medications are potent agents for weight loss, they are not a standalone solution and long-term success hinges on ongoing behavioural management.
